BioLineRx Ltd.
A clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases.
BLRX | TA
Overview
Corporate Details
- ISIN(s):
- US09071M2052 (+1 more)
- LEI:
- 529900AKIOSC15Y63R18
- Country:
- Israel
- Address:
- Modi'in Technology Park, 2 HaMa'ayan Street, 7177871 Modi'in
- Website:
- https://www.biolinerx.com/
- Sector:
- Manufacturing
Description
BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-01-07 18:24 |
PROSPECTUS SUPPLEMENT
|
English | 36.2 KB | ||
| 2025-01-06 17:05 |
BioLineRx Announces $10 Million Registered Direct Offering
|
English | 68.3 KB | ||
| 2025-01-06 17:05 |
BioLineRx Announces $10 Million Registered Direct Offering
|
English | 36.3 KB | ||
| 2024-12-29 01:59 |
Form S-8
|
English | 248.6 KB | ||
| 2024-12-29 01:59 |
Form S-8
|
English | 36.2 KB | ||
| 2024-11-25 15:05 |
BioLineRx Reports Third Quarter 2024 Financial Results
|
English | 427.8 KB | ||
| 2024-11-25 15:05 |
BioLineRx Reports Third Quarter 2024 Financial Results
|
English | 36.5 KB | ||
| 2024-11-21 14:44 |
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commerciali…
|
English | 491.1 KB | ||
| 2024-11-21 14:44 |
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commerciali…
|
English | 36.4 KB | ||
| 2024-11-21 14:43 |
PROSPECTUS SUPPLEMENT
|
English | 653.4 KB | ||
| 2024-11-21 14:43 |
PROSPECTUS SUPPLEMENT
|
English | 36.2 KB | ||
| 2024-11-21 10:35 |
The company intends to publish an immediate report about a material event, trad…
|
Hebrew (modern) | 103.1 KB | ||
| 2024-11-13 16:22 |
Received a letter from Nasdaq advising that the Company had been granted a 180-…
|
English | 63.0 KB | ||
| 2024-11-13 16:22 |
Received a letter from Nasdaq advising that the Company had been granted a 180-…
|
English | 36.5 KB | ||
| 2024-11-05 17:05 |
BioLineRx Announces Oral Presentation at ASH 2024
|
English | 527.6 KB |
Automate Your Workflow. Get a real-time feed of all BioLineRx Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioLineRx Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioLineRx Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
